Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring

  • End date
    Oct 30, 2023
  • participants needed
  • sponsor
    Baker Heart and Diabetes Institute
Updated on 1 February 2021


The overall goal of this study is to develop a combined polygenic risk score (PRS) and metabolic risk score (MRS) and determine its impact on selecting community members for CCS. The trial component of this study will compare the use of these scores to motivate people to adhere to therapy, an ongoing challenge for clinicians, by providing feedback in a meaningful form to both the clinicians and the patients.


Patients undergoing a polygenic risk score (PRS), metabolic risk score (MRS) and coronary calcium score (CCS) will be randomized to receive PRS and CCS information and followed for the reduction of risk over 12 months. This information will provide information about how to motivate people to adhere to therapy, by providing feedback in a meaningful form to both the clinicians and the patients.

Condition Coronary Artery Disease, Coronary heart disease, Cardiac Ischemia, Myocardial Ischemia
Treatment Polygenic Risk Score, Coronary Calcium Score
Clinical Study IdentifierNCT04604353
SponsorBaker Heart and Diabetes Institute
Last Modified on1 February 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 40 yrs and 70 yrs?
Gender: Male or Female
Do you have any of these conditions: Myocardial Ischemia or Coronary heart disease or Cardiac Ischemia or Coronary Artery Disease?
Asymptomatic subjects age 40-70y
Statin nave
TC 6.5 mmol/L and LDLC <5 mmol/L, and
5 year Australian risk 2%

Exclusion Criteria

Symptomatic coronary, cerebrovascular, or peripheral vascular disease
Intolerance of statins or currently on statins for any length of time
Pre-existing muscle disease (eg polymyositis, fibromyalgia) - this may be confused with myalgia from statins
Patients on drugs that increase the risk of myopathy/rhabdomyolysis such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV/hepatitis C protease inhibitors)
Atrial fibrillation (interferes with CTCA)
Chronic kidney disease on haemodialysis (because of vascular calcification) or GFR <50ml/min per 1.73m2 using the Modification of Diet in Renal Disease (MDRD) formula
Inability to provide informed consent
Major systemic illness eg. malignancy; rheumatoid arthritis
Women of child bearing potential (due to performance of CT)
Poorly controlled hypertension: SBP> 200 and or DBP > 100
Severe psychiatric disorder (eg bipolar depression; psychosis)
Patients eligible for treatment based on current Australian guidelines (5 year risk >15%)
Patients eligible for treatment based on current PBS thresholds TC >7.5 mmol/l and other criteria (see below)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note